For investors looking for chances where the market price may not completely show a company's actual value, a systematic filtering process can help find possible choices. One such way is to search for stocks that join a good valuation score with acceptable results in other basic areas like earnings, financial condition, and expansion. This technique tries to find companies that are not only low-priced by the numbers but are also supported by fair business strength, possibly providing a safety buffer, a central idea of value investing. This plan tries to steer clear of "value traps," where a low price signals a basic worsening, by checking that other financial measures are healthy.
Soleno Therapeutics Inc (NASDAQ:SLNO), a clinical-stage biopharmaceutical company working on rare diseases, recently appeared from such a "fair value" filter. The filter selected for stocks with a high ChartMill Valuation Rating (more than 7 out of 10) while also needing at least fair scores in earnings, condition, and expansion. Soleno's basic report shows a total rating of 6/10, but its detailed part scores display a picture that matches this value-focused search.
Valuation: The Center of the Chance
The main draw for a value investor is Soleno's valuation rating of 8. While the company's past Price-to-Earnings (P/E) ratio seems elevated at 146.76, this is mainly due to its clinical-stage position and recent move to profitability. More future-oriented measures show a different view:
- Forward P/E Ratio: An important number of 7.86, which is much lower than 98% of its biotechnology industry group and also under the S&P 500 average.
- Enterprise Value to EBITDA: The company is priced low compared to almost 90% of the industry by this measure.
- Price to Free Cash Flow: This ratio also points to a quite low price, with SLNO costing less than 94% of its industry rivals.
- PEG Ratio: The small PEG ratio, which changes the P/E for estimated earnings expansion, hints the present share price may not be completely including the company's future possibility.
For a value investor, these measures imply the market might be using a wide reduction or not completely valuing the company's future outlook, making a possible difference between market price and real worth.
Financial Condition: A Firm Base
A good balance sheet is key for handling ups and downs and paying for future expansion, particularly for a development-stage biotech. Soleno gets a solid Condition rating of 8, giving that needed safety buffer. Important positives contain:
- Good Solvency: An Altman-Z score of 9.14 shows a very small short-term chance of failure and does better than over 81% of the industry.
- Controlled Debt: The Debt to Free Cash Flow ratio is a strong 1.07, meaning the company could pay off all its debt with just a bit more than a year of its present free cash flow. This does better than 94% of similar companies.
- High Liquidity: Current and Quick Ratios of 5.80 and 5.55, in that order, show the company has enough means to cover its short-term needs with a good extra amount.
This financial steadiness lowers the chance linked to putting money in a company that is not yet selling products widely, a key point when judging possibly under-priced cases.
Earnings and Expansion: Signals of a Change
While Soleno's total Earnings rating is a middle 5, recent patterns and profit levels show encouraging gain. The company was profitable over the last year and made positive operating cash flow. Even more notable, its profit levels are some of the top in its field:
- Profit Margin: At 10.75%, it is higher than 91% of biotechnology companies.
- Operating Margin: At 4.94%, it does better than almost 90% of the industry.
- Gross Margin: A very high 98.58%.
The Expansion rating of 4 is supported by strong future guesses, which are important for a value investor judging future real worth. Experts predict fast growth:
- Earnings Per Share (EPS) is guessed to increase by an average of 256.59% each year.
- Revenue is expected to increase by an average of 77.87% each year.
This expected expansion path is central to the investment idea. If these guesses happen, today's valuation numbers could seem very low later. The high future expansion rates help support the filter's need for a "fair" expansion score next to good value measures.
End and Investor Points
Soleno Therapeutics shows a picture that matches a particular value-investing filter: a stock with an appealing price compared to its future possibility, held up by a very strong balance sheet and new profitability with top profit levels. The company's main drug candidate, DCCR for Prader-Willi syndrome, has Breakthrough Therapy status, and its success is the main force behind the high expansion guesses. The investment idea depends on the market correctly valuing this possibility, which the present valuation measures hint it may not completely be doing.
Still, this is not free of chance. The company's past finances show years of losses, which is normal for clinical-stage biotech. The whole idea looks to the future and relies on successful product sales. Investors must do their own complete checking beyond these number scores.
This examination used Soleno's basic report, which you can look at closely here.
If you want to find other companies that meet similar "fair value" needs, joining good valuation with firm basics, you can use the same filter yourself. Click here to see the filter and view more possible outcomes.
Notice: This article is for information only and is not financial guidance, a suggestion, or a deal to buy or sell any investments. The information given uses supplied data and is thought to be dependable; however, its correctness is not assured. Putting money at risk involves chance, including the possible loss of the original amount. You should do your own study and talk with a skilled financial guide before making any investment choices.